SCHEDULE: Vanguard Group Amends Syndax Pharma Stake to 0%

The Vanguard Group reported a 0% beneficial ownership in Syndax Pharmaceuticals Inc. common stock due to an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 2 to Schedule 13G for Syndax Pharmaceuticals Inc.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Syndax Pharmaceuticals Inc. common stock.
• This change is attributed to an internal realignment within The Vanguard Group, effective January 12, 2026.
• Following this realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report their beneficial ownership separately.
• The Vanguard Group, Inc. itself no longer has, or is deemed to have, beneficial ownership over securities held by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for Syndax Pharmaceuticals Inc., as the change in beneficial ownership to 0% by The Vanguard Group is due to an internal reporting realignment rather than a divestment of all Vanguard-managed funds.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Syndax Pharmaceuticals Inc. or The Vanguard Group's future investment strategies beyond the reporting realignment.

Management Comments

• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that such internal realignments by large institutional investors like The Vanguard Group are primarily administrative and do not necessarily reflect a change in investment thesis regarding the underlying company, Syndax Pharmaceuticals Inc. Other Vanguard-affiliated entities may still hold shares, but will now report them independently.

Stakeholder Impact

• Shareholders of Syndax Pharmaceuticals Inc. should be aware that The Vanguard Group, as a single reporting entity, no longer holds beneficial ownership, though other Vanguard-affiliated funds may still hold shares and will report them separately.

Key Dates

Keywords

Syndax Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Corporate Realignment